Twice daily ceftriaxone therapy for serious bacterial infections in children

Tasnee Chonmaitree, Blaise L. Congeni, Jose Munoz, Tamara A. Rakusan, Keith R. Powell, Quellin T. Box

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The clinical efficacy and safety of ceftriaxone, a long half-life cephalosporin were evaluated in 48 children with a variety of serious bacterial infections. Clinical cure was achieved in 92% (44 of 48) of patients. Peak serum bactericidal titres for Haemophilus influenzae type b, Streptococcus pneumoniae, Str. pyogenes and Escherichia coli were ≧ 1 :1024. Mean peak and trough ceftriaxone levels were 173 and 42 mg/1, respectively. Mild and transient diarrhoea was observed in 10% of patients. Laboratory side effects encountered were eosinophilia, thrombocytosis and neutropenia in another 8%. Ceftriaxone is a useful antibiotic for common childhood infections. Its prolonged half-life allows twice daily administration which reduces problems related to intravenous therapy as well as the cost and personnel time.

Original languageEnglish (US)
Pages (from-to)511-516
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Issue number5
StatePublished - May 1984
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Twice daily ceftriaxone therapy for serious bacterial infections in children'. Together they form a unique fingerprint.

Cite this